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A b s t r a c t
Introduction: Whether duration of chronic total occlusion (CTO) affects lesion and procedural characteristics remains largely 
unknown. 
Aim: To investigate whether CTO duration influences lesion characteristics and revascularization success. 
Material and methods: EuroCTO Registry data on patients who had CTO percutaneous coronary intervention between January 
2015 and April 2017 were analyzed. Three groups were created based on occlusion age: 3 to 6 months (n = 1415), 7 to 12 months 
(n = 973), > 12 months (n = 1656). 
Results: Patients with greater CTO duration were older (63.0 (56.0–70.0); 63.0 (56.0–71.0); 66.0 (59.0–73.0) years respectively; 
p < 0.001), had more 3-vessel disease (32.2%; 30.9%; 46.1% respectively; p < 0.001) and more frequent prior coronary artery bypass 
grafting (8.2%; 9.9%; 29.4% respectively; p < 0.001). In multivariate analysis, occlusion duration was associated with moderate/
severe calcification (OR = 1.52; 95% CI: 1.28–1.80; p < 0.001), lesion length > 20 mm (OR 1.77; 95% CI 1.49–2.10; p < 0.001), and 
collateral circulation Werner type 2 (OR = 1.20; 95% CI: 1.01–1.43; p = 0.041). The CTO duration was associated with lower proce-
dural success (OR for success 0.60; 95% CI: 0.46–0.79; p < 0.001). In multivariate analysis in-hospital adverse events did not differ 
according to duration of CTO.
Conclusions: Coronary artery CTO duration is associated with greater extent of calcification, lesion length, development of col-
lateral circulation and, most importantly, with lower procedural success.
Key words: chronic total occlusion, lesion characteristics, percutaneous coronary intervention. 
S u m m a r y
In our study, longer chronic total occlusion (CTO) duration was associated with longer procedure time, greater volume of 
dye used and lower revascularization success. However, it did not influence the in-hospital adverse event rate. This should be 
taken into account when planning procedures of CTO older than 12 months. Moreover, in our study longer CTO duration was 
associated with lower procedural success. 
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Introduction
Chronic total occlusion (CTO) is present in about 
16% to 30% of patients undergoing coronary angiogra-
phy [1–3]. Despite the increased experience due to the 
growth of the number of the performed procedures and 
the introduction of new techniques and equipment, CTO 
still remains one of the most demanding procedures in 
interventional cardiology. Using large registry databases, 
differences in outcomes and revascularization success in 
patients with CTO were published during the past years 
[4–9]. However, as determining age of the CTO may be 
very challenging, most of them did not include this factor 
in the analysis. There are several reports describing how 
and whether CTO duration may affect lesion and proce-
dural characteristics [10–14]. 
However, none of those studies focused on such 
a  large cohort of patients treated in recent years, and 
therefore benefiting the most from the latest develop-
ments in the field of CTO. 
Material and methods
The European Registry of CTOs (ERCTO) is a prospec-
tive real-world monitored based registry involving over 
100 centers across Europe including patients treated 
with CTO percutanous coronary intervention (PCI) [6].
For the purpose of our study we included patients 
admitted to the hospitals between January 2015 and 
the end of April 2017. The treatment indication for CTO 
was symptomatic myocardial ischemia and/or evidence 
of reversible myocardial ischemia by perfusion imaging 
or stress testing. Registry data from both members and 
associates of the Euro CTO Club were included. Only pa-
tients with certain or likely CTO duration were included 
in the analysis. Out of 10699 patients in the database re-
cruited during the selected period of time, 5933 patients 
were excluded due to undetermined age of the occlusion. 
Out of the remaining 4766 patients we excluded 287 pa-
tients with an additional acute coronary syndrome and 
435 patients with insufficient further data regarding the 
occlusion characteristics. In the end, a total of 4044 pa-
tients were included in the data analysis (Figure 1). Pa-
tients were divided into 3 groups according to age of the 
CTO: 1) 3–6 months; 2) 7–12 months; 3) over 12 months.
Coronary CTO was defined as angiographic evidence 
of total occlusions with thrombolysis in myocardial in-
farction (TIMI) flow grade of 0 and estimated duration 
of at least 3 months. The length of coronary occlusions 
was estimated from angiographic projections. Degree 
of calcification was estimated visually on fluoroscopy. 
Moderate and severe calcifications were defined as cal-
cium extending for less than half or equal/greater than 
half of the total CTO segment, respectively. The assess-
ment of collateral connections was made according to 
the Werner classification (CC) [15]. Occlusion duration 
in the ERCTO was divided into 3 levels of certainty (cer-
tain and angiographically confirmed; likely and clinical-
ly confirmed; undetermined), as suggested by the Euro 
CTO Club consensus document [16]. Procedural success 
was defined as angiographic success (final residual ste-
nosis < 30% by visual estimation and TIMI flow grade 
of 3 after CTO recanalization). In-hospital adverse events 
(AEs) were defined as the composite of non-Q-wave and 
Q-wave myocardial infarction (MI), coronary perforation 
requiring intervention, recurrent angina requiring urgent 
repeat revascularization with PCI or coronary bypass sur-
gery, major bleeding, stent thrombosis, stroke, and death. 
The complexity of CTO lesion was assessed through the 
J-CTO (Multicenter CTO Registry in Japan) score and the 
clinical and lesion-related (CL) score [17, 18]. 
Statistical analysis 
Categorical variables are presented as counts and 
percentages (%). The median (25th–75th percentiles) is re-
ported for continuous data. Fisher’s exact test or c2 test 
was used for categorical variables, and the Mann-Whit-
ney U  test was used to compare continuous variables. 
Multivariable logistic regression analyses were per-
formed to determine the independent predictors for le-
sion and procedural characteristics. Univariate analysis 
was performed for all variables in the study, then the 
variables with p < 0.05 were included in the multivariable 
models for adjusted analysis. Statistical analyses were 
performed with R 3.4. 
Results
A total of 4044 of patients were included in the main 
analysis. Patients with the longest CTO duration as com-
pared to patients with CTO duration 3–6 months were 
Figure 1. Flow chart. Out of 10699 patients in the 
database recruited during the selected period of 
time, 5933 patients were excluded due to unde-
termined age of the occlusion. Out of the remain-
ing 4766 patients we excluded 287 patients with 
an additional acute coronary syndrome and 435 
patients with insufficient further data regarding 
the occlusion characteristics. In the end a total of 
4044 patients were included in the data analysis
10,699 patients in the European registry  
of CTOs
5,933 patients excluded due to  
undetermined age of occlusion
4,766 patients with confirmed  
CTO duration
435 patients excluded due to insufficient 
data regarding lesion characteristics
4,044 patients analyzed
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significantly older (63.0 (56.0–70.0) vs. 66.0 (59.0–73.0) 
years) and had higher prevalence of peripheral artery 
disease (8.8% vs. 12.4%) (Table I). The group with the 
longest CTO duration had higher incidence of myocardial 
infarction (MI) and prior coronary artery bypass grafting 
(CABG) as compared to other groups. Lesion and pro-
Table I. Clinical characteristics of patients depending on the chronic total occlusion age
Parameter 3–6 months
(n = 1415)
7–12 months
(n = 973)
> 12 months
(n = 1656)
Overall p-value
Age [years] 63.0 (56.0–70.0) 63.0 (56.0–71.0) 66.0 (59.0–73.0) < 0.001
Gender (male), n (%) 1197 (84.7) 812 (83.5) 1440 (87.0) 0.030
BMI [kg/m2] 27.8 (25.3–31.1) 27.8 (25.3–31.1) 28.3 (25.6–31.1) 0.077
Hypertension, n (%) 1097 (77.5) 787 (80.9) 1369 (82.7) 0.002
Diabetes, n (%) 426 (31.8) 288 (31.6) 539 (35.4) 0.062
Hypercholesterolemia, n (%) 1137 (80.4) 762 (78.3) 1317 (79.5) 0.479
Smokers, n (%) 334 (25.0) 220 (24.1) 299 (19.6) 0.001
PAD, n (%) 124 (8.8) 98 (10.1) 206 (12.4) 0.004
Previous MI, n (%) 557 (40.0) 394 (41.1) 818 (51.2) < 0.001
Previous CABG, n (%) 116 (8.2) 96 (9.9) 486 (29.4) < 0.001
Previous PCI, n (%) 682 (48.2) 481 (49.4) 913 (55.2) < 0.001
GFR [ml/min/1.73 m2] 91.2 (70.4–111.3) 91.2 (71.6–112.2) 84.0 (66.7–108.2) < 0.001
Left ventricular EF < 35, n (%) 78 (5.5) 49 (5.1) 120 (7.3) 0.039
3-vessel disease, n (%) 449 (32.2) 294 (30.9) 749 (46.1) < 0.001
Values are median (25th–75th percentile) or n (%). BMI – body mass index, CABG – coronary artery bypass grafting, EF – ejection fraction, GFR – glomerular filtration 
rate, MI – myocardial infarction, PAD – peripheral artery disease, PCI – percutaneous coronary intervention. 
Table II. Lesion characteristics depending on the chronic total occlusion age
Parameter 3–6 months
(n = 1415)
7–12 months
(n = 973)
> 12 months
(n = 1656)
Overall p-value
CTO artery 0.001
RCA, n (%) 773 (54.7) 545 (56.0) 998 (60.3)
LM, n (%) 6 (0.4) 5 (0.5) 19 (1.1)
LAD, n (%) 393 (27.8) 250 (25.7) 342 (20.7)
Cx, n (%) 235 (16.6) 168 (17.3) 288 (17.4)
CTO in bypass, n (%) 5 (0.4) 5 (0.5) 8 (0.5)
Ostial CTO, n (%) 154 (10.9) 102 (10.5) 254 (15.4) < 0.001
Vessel diameter [mm] 3.0 (2.5–3.0) 3.0 (2.7–3.0) 3.0 (2.7–3.0) 0.006
CTO length [mm] 20.0 (15.0–30.0) 25.0 (15.0–30.0) 28.0 (20.0–40.0) < 0.001
Collateral circulation type 2, n (%) 333 (24.7) 274 (29.5) 474 (30.1) 0.002
Proximal tortuosity, n (%) 271 (19.4) 162 (16.9) 332 (20.6) 0.073
In CTO bend, n (%) 388 (27.5) 330 (34.2) 614 (37.3) < 0.001
Moderate and severe calcification, 
n (%)
486 (34.4) 370 (38.3) 851 (51.6) < 0.001
Blunt stump, n (%) 610 (43.3) 405 (41.7) 734 (44.5) 0.366
Severe distal disease, n (%) 475 (34.5) 353 (38.0) 783 (48.8) < 0.001
Values are median (25th–75th percentile) or n (%). CTO – chronic total occlusion, Cx – circumflex artery, LAD – left anterior descending artery, LM – left main artery, 
RCA – right coronary artery.
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cedural characteristics also differed between patients 
with different age of the CTO (Tables II, III). Patients 
with the longest CTO duration as compared to patients 
with CTO duration 3–6 months had longer occlusions 
(28.0 (20.0–40.0) vs. 20.0 (15.0–30.0) mm), more calci-
fied lesions (calcification moderate or severe; 51.6% vs. 
34.4%), better collateral circulation (30.1% vs. 24.7% for 
CC2) and more advanced coronary artery disease distal 
to CTO (48.8% vs. 34.5%). The revascularization success 
rate was the highest in the patients with CTO duration 
3–6 months as compared to the patients with the oldest 
CTO (92.1% vs. 83.5%), and the retrograde approach was 
less common in those lesions (24.2% vs. 38.5%). Intra-
vascular ultrasound was used more frequently in the old-
er occlusions (15.7% vs. 9.5%). Incidence of in-hospital 
AEs increased from 2.0% in the group with the shortest 
CTO duration to 3.6% in the group with the longest CTO 
duration (Table III). Time of the procedure and dye vol-
ume increased significantly with increased CTO duration, 
reaching up to 120 min and 250 ml of dye used in the 
last group (Table III). The J-CTO score as well as the CL 
score were higher in older lesions (Figure 2).
In multivariate analysis (univariate analysis is pre-
sented in Table IV) we found that CTO duration was an 
Table III. Procedural characteristics depending on the chronic total occlusion age
Parameter 3–6 months
(n = 1415)
7–12 months
(n = 973)
> 12 months
(n = 1656)
Overall p-value
One or more previous attempts, 
n (%)
470 (33.2%) 319 (32.8%) 563 (34.0%) 0.789
Retrograde approach, n (%) 342 (24.2%) 237 (24.4%) 638 (38.5%) < 0.001
Procedural failure, n (%) 112 (7.9%) 109 (11.2%) 273 (16.5%) < 0.001
AE, n (%) 29 (2.0%) 24 (2.5%) 60 (3.6%) 0.024
Procedure time 85.0 (57.0–120.0) 90.0 (63.0–127.0) 120.0 (77.0–162.0) < 0.001
Fluoroscopy time 31.5 (19.0–53.0) 32.5 (20.0–52.0) 45.0 (27.0–70.0) < 0.001
Dye used 237.0 (170.0–330.0) 250.0 (170.0–350.0) 250.0 (190.0–350.0) < 0.001
Values are median (25th–75th percentile) or n (%). AE – adverse events. 
Figure 2. Differences in J-CTO score (A) and CL score (B) depending on the chronic total occlusion age. Differ-
ences in J-CTO score between patients with different chronic total occlusion (CTO) duration were significant 
(3968 patients; p < 0.001). J-CTO score of 3 or more increased with increase of the lesion age. In the CL score 
only patients with a first attempt were included in the analysis (2692 patients). Differences in CL score depend-
ing on the occlusion duration were significant (p < 0.001) and prevalence of a CL score of more than 5 points 
increased with the lesion age
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independent predictor of lesion length, severity of calcifi-
cation, better developed collateral circulation and proce-
dure failure, but it did not influence the AE rate (Table V). 
Full multivariate analysis is presented in Table VI. 
Differences between patients with undetermined age 
of the occlusion and known occlusion duration are pre-
sented in the Supplement (Table VII). As expected, pa-
tients with determined age of occlusion had previous MI 
and CABG more frequently (37.5% vs. 44.8% and 8.1% 
vs. 17.3% respectively). The procedural failure rate was 
similar in both groups (11.9% vs. 12.2%). Interestingly, 
incidence of AEs was higher in the group with undeter-
mined age of the occlusion (3.7% vs. 2.8%). 
Discussion
Our study, performed on a  large cohort of patients, 
demonstrated that: 1) longer duration of CTO is associ-
ated with longer procedure and fluoroscopy time, and 
greater amount of dye used; 2) longer duration of CTO 
is a predictor of greater calcification, longer lesions and 
more developed collateral circulation; 3) age of the CTO 
influences the procedure success, but not in-hospital AEs. 
Procedure duration
As observed in previous studies, patients with longer 
CTO duration had longer procedure and fluoroscopy time, 
as well as a greater amount of dye used [10]. These re-
sults should be taken into account when planning a pro-
cedure with known age of the CTO. 
Calcification
In our study occlusion duration of over 12 months 
was an independent predictor of calcification. In more 
advanced coronary artery disease (CAD), elevated lipid 
content and inflammatory mediators induce osteogenic 
differentiation of vascular smooth muscle cells in the in-
tima – usually calcific deposits are found more frequently 
and in greater amounts among more advanced lesions 
and in elderly individuals [19]. These observations were 
confirmed in the CTO histopathology study where old-
er lesion age was associated with a greater fibrocalcific 
component [20]. Comparable to our results, Danek et al. 
recently observed a  difference of 16% in moderate/se-
vere calcification between patients with a CTO duration 
shorter than 5 and longer than 36.3 months [10]. More-
over, as previously reported, CABG in medical history was 
also associated with higher prevalence of calcification in 
CTO lesions [21]. Importantly, calcification is regarded as 
one of the predictors of failure when performing PCI of 
CTO – both the CL score proposed by Alessandrino et al. 
and the J-CTO score include calcification in their scoring 
systems [17, 18]. 
Collateral circulation
We observed that occlusion duration longer than 
6 months was a predictor of development of collaterals 
in CC grade 2 proposed by Werner et al. [15]. Time of re-
cruitment of collaterals in CTO is still debatable, ranging 
from several weeks to months [22]. Collateral flow plays 
several major roles in CTO. First, well-developed collater-
als have the capacity to prevent myocardial necrosis and 
may preserve myocardial viability [22]. Second, collater-
als are used during the retrograde approach and thus 
poorly developed collaterals were found to be an inde-
pendent predictor of technical failure in CTO PCI [5, 23]. 
Lesion length
In contrast to the study of Danek et al., we found 
that CTO length increased with age of the CTO [10]. In 
our study, even occlusion duration longer than 6 months 
was an independent predictor of CTO length over 20 mm. 
One could speculate that with the novel techniques in-
cluding the hybrid approach and retrograde revascular-
ization lesion length may be less important in assess-
ing complexity of the CTO procedures as shown in the 
PROGRESS CTO score and ORA score [5, 23]. In contrast, 
Ellis et al. showed in their recent study assessing pre-
dictors of a  successful hybrid approach that procedure 
failure is correlated with occlusion length over 10 mm 
[7]. Besides that, longer lesions may still influence the 
duration of the procedure [17]. 
Procedural success
Currently several different angiographic scoring sys-
tems assessing predictors of failure and success in CTO 
PCI are available, but none of them has ever included the 
duration of CTO in their analysis [24–26]. On the other 
hand, CTO duration as predictor of revascularization fail-
ure has been described in computed tomography studies 
[13, 14]. Given the results of those studies and our cur-
rent study, it is plausible to say that duration of CTO may 
have an influence on procedural success and PCI of CTO 
should not be postponed, although this observation mer-
its further research. Nevertheless, it should be underlined 
that in our study the exact age of CTO lesions could only 
be determined in less than 50% of the cases; thus imple-
menting CTO duration in future scoring systems may be 
challenging. Lastly, some of the studies did not find a cor-
relation between CTO duration and procedural success; 
however, the number of patients included in the analysis 
was also significantly lower [27]. 
Adverse events
A weighted meta-analysis by Patel et al. with 18061 
patients included from 65 studies revealed low rates of 
AEs in patients undergoing CTO PCI [2]. In our study rates 
of AEs were comparable, with 0.4% deaths and 0.7% MI 
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Table IV. Univariate analysis for lesion characteristics
Parameter P-value
Age [years] 63.0 (55.0–70.0) 66.0 (59.0–74.0) < 0.001
Gender (male), n (%) 1961 (84.6) 1472 (86.3) 0.139
BMI [kg/m2] 27.8 (25.4–31.1) 28.1 (25.5–31.2) 0.135
Hypertension, n (%) 1808 (77.9) 1435 (84.1) < 0.001
Hypercholesterolemia, n (%) 1819 (78.4) 1385 (81.1) 0.037
Diabetes, n (%) 640 (29.5) 609 (38.4) < 0.001
Smoker, n (%) 544 (25.1) 305 (19.2) < 0.001
PAD, n (%) 187 (8.1) 239 (14.0) < 0.001
COPD, n (%) 85 (3.7) 110 (6.4) < 0.001
Prior stroke, n (%) 64 (2.8) 45 (2.6)
Previous MI, n (%) 1047 (45.9) 714 (43.2) 0.1
Previous CABG, n (%) 269 (11.6) 426 (25.0) < 0.001
Previous PCI, n (%) 1144 (49.3) 922 (54.0) 0.004
GFR [ml/min/1.73 m2] 91.2 (71.5–113.6) 84.2 (65.5–107.2) < 0.001
Left ventricular EF < 35%, n (%) 143 (6.2) 103 (6.1) 0.91
Number of diseased vessels, n (%): < 0.001
1-vessel disease 823 (36.2) 392 (23.3)
2-vessel disease 736 (32.4) 514 (30.6)
3-vessel disease 715 (31.4) 773 (46.0)
CTO artery, n (%): < 0.001
RCA 1248 (53.9) 1061 (62.2)
LAD 597 (25.8) 383 (22.4)
Cx 451 (19.5) 235 (13.8)
LM 3 (0.1) 27 (1.6)
CTO in bypass 17 (0.7) 1 (0.1)
CTO in side branch 78 (3.4) 34 (2.0) 0.012
Ostial CTO 227 (9.8) 281 (16.5) < 0.001
Occlusion duration, n (%): < 0.001
3–6 months     486 (28.5)        925 (39.9)    
7–12 months     370 (21.7)        596 (25.7)    
Over 12 months     851 (49.9)        799 (34.4)    
Parameter CC2
(n = 2772)
CC0/CC1
(n = 1081)
P-value
Age [years] 64.0 (57.0–72.0) 64.0 (57.0–72.0) 0.917
Gender (male), n (%) 2331 (84.2) 951 (88.0) 0.003
BMI [kg/m2] 28.1 (25.4–31.1) 27.8 (25.4–31.1) 0.372
Hypertension, n (%) 2236 (80.7) 864 (79.9) 0.636
Hypercholesterolemia, n (%) 2206 (79.6) 859 (79.5) 0.97
Diabetes, n (%) 878 (33.7) 308 (30.7) 0.087
Smoker, n (%) 592 (22.7) 231 (23.0) 0.9
PAD, n (%) 282 (10.2) 127 (11.7) 0.171
COPD, n (%) 133 (4.8) 57 (5.3) 0.597
Prior stroke, n (%) 71 (2.6) 34 (3.1) 0.373
Previous MI, n (%) 1214 (44.8) 464 (44.1) 0.743
Previous CABG, n (%) 448 (16.2) 214 (19.8) 0.008
Previous PCI, n (%) 1428 (51.5) 550 (50.9) 0.742
GFR [ml/min/1.73 m2] 89.0 (68.8–110.7) 89.1 (69.8–111.3) 0.5
Left ventricular EF < 35%, n (%) 182 (6.6) 48 (4.5) 0.018
Moderate/severe calcification 
(n = 2320)
Mild/no calcification  
(n = 1701)
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Parameter P-value
Number of diseased vessels, n (%): < 0.001
1-vessel disease 790 (28.9) 372 (35.4)
2-vessel disease 873 (32.0) 323 (30.7)
3-vessel disease 1067 (39.1) 357 (33.9)
CTO artery, n (%): < 0.001
RCA 1555 (56.2) 681 (63.0)
LAD 666 (24.1) 261 (24.1)
Cx 521 (18.8) 126 (11.7)
LM 14 (0.5) 12 (1.1)
CTO in bypass 12 (0.4) 1 (0.1)
CTO in side branch 96 (3.5) 10 (0.9) < 0.001
Ostial CTO 330 (11.9) 163 (15.2) 0.008
Occlusion duration, n (%): 0.003
3–6 months     333 (30.8)       1013 (36.5)    
7–12 months     274 (25.3)        656 (23.7)    
Over 12 months     474 (43.8)       1103 (39.8)    
Parameter Lesion length < 20 mm  
(n = 1167)
Lesion length > 20 mm  
(n = 2832)
P-value
Age [years] 65.0 (58.0–73.0) 64.0 (57.0–71.0) 0.015
Gender (male), n (%) 973 (83.4) 2438 (86.1) 0.034
BMI [kg/m2] 27.8 (25.3–30.8) 28.0 (25.5–31.2) 0.032
Hypertension, n (%) 930 (79.7) 2287 (80.8) 0.467
Hypercholesterolemia, n (%) 944 (80.9) 2237 (79.0) 0.19
Diabetes, n (%) 356 (32.3) 885 (33.7) 0.45
Smoker, n (%) 233 (21.2) 614 (23.4) 0.155
PAD, n (%) 100 (8.6) 322 (11.4) 0.01
COPD, n (%) 51 (4.4) 144 (5.1) 0.383
Prior stroke, n (%) 32 (2.7) 78 (2.8) 1
Previous MI, n (%) 471 (41.2) 1282 (46.4) 0.003
Previous CABG, n (%) 163 (14.0) 524 (18.5) 0.001
Previous PCI, n (%) 551 (47.2) 1497 (52.9) 0.001
GFR [ml/min/1.73 m2] 87.0 (68.5–108.2) 89.2 (69.1–111.4) 0.159
Left ventricular EF < 35%, n (%) 68 (5.9) 178 (6.3) 0.629
Number of diseased vessels, n (%): 0.044
1-vessel disease 372 (32.6) 838 (30.1)
2-vessel disease 376 (32.9) 867 (31.2)
3-vessel disease 394 (34.5) 1078 (38.7)
CTO artery, n (%): < 0.001
RCA 538 (46.2) 1747 (61.7)
LAD 349 (30.0) 629 (22.2)
Cx 263 (22.6) 421 (14.9)
LM 12 (1.0) 18 (0.6)
CTO in bypass 2 (0.2) 16 (0.6)
CTO in side branch 59 (5.1) 51 (1.8) < 0.001
Ostial CTO 110 (9.4) 389 (13.8) < 0.001
Occlusion duration, n (%): < 0.001
3–6 months     514 (44.0)        890 (31.4)    
7–12 months     277 (23.7)        687 (24.3)    
Over 12 months     376 (32.2)       1255 (44.3)    
CC2
(n = 2772)
CC0/CC1
(n = 1081)
Table IV. Cont.
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Parameter P-value
Age [years] 66.0 (60.0–73.0) 64.0 (57.0–72.0) < 0.001
Gender (male), n (%) 423 (85.8) 3026 (85.3) 0.804
BMI [kg/m2] 28.4 (26.0–31.6) 27.9 (25.4–31.1) 0.014
Hypertension, n (%) 410 (83.0) 2843 (80.1) 0.142
Hypercholesterolemia, n (%) 386 (78.1) 2830 (79.7) 0.45
Diabetes, n (%) 181 (39.4) 1072 (32.4) 0.003
Smoker, n (%) 92 (20.0) 761 (23.0) 0.179
PAD, n (%) 80 (16.2) 348 (9.8) < 0.001
COPD, n (%) 40 (8.1) 156 (4.4) 0.001
Prior stroke, n (%) 22 (4.5) 88 (2.5) 0.017
Previous MI, n (%) 234 (49.0) 1535 (44.3) 0.059
Previous CABG, n (%) 115 (23.3) 583 (16.4) < 0.001
Previous PCI, n (%) 299 (60.5) 1777 (50.1) < 0.001
GFR [ml/min/1.73 m2] 84.7 (66.4–106.9) 89.1 (69.4–111.0) 0.016
Left ventricular EF < 35%, n (%) 34 (7.0) 213 (6.0) 0.488
Number of diseased vessels, n (%): 0.213
1-vessel disease 136 (28.2) 1086 (31.2)
2-vessel disease 148 (30.7) 1106 (31.7)
3-vessel disease 198 (41.1) 1294 (37.1)
CTO artery, n (%): 0.02
RCA 316 (64.0) 2000 (56.4)
LAD 102 (20.6) 883 (24.9)
Cx 74 (15.0) 617 (17.4)
LM 1 (0.2) 29 (0.8)
CTO in bypass 1 (0.2) 17 (0.5)
CTO in side branch 10 (2.0) 102 (2.9) 0.35
Ostial CTO 97 (19.7) 413 (11.7) < 0.001
In stent CTO 31 (6.3) 367 (10.3) 0.006
Bifurcation, n (%) 130 (26.3) 992 (27.9) 0.482
Vessel diameter [mm] 3.0 (2.8–3.0) 3.0 (2.5–3.0) 0.839
CTO length [mm] 30.0 (20.0–40.0) 25.0 (15.0–35.0) < 0.001
Collateral circulation type 2, n (%) 118 (25.1) 963 (28.5) 0.135
Proximal tortuosity, n (%) 134 (27.7) 631 (18.1) < 0.001
In CTO bend, n (%) 254 (52.4) 1078 (30.5) < 0.001
Moderate and severe calcification, n (%) 307 (62.8) 1400 (39.6) < 0.001
Blunt stump, n (%) 243 (49.4) 1506 (42.6) 0.005
Side branch 3 mm proximal to CTO, n (%) 133 (26.9) 943 (26.6) 0.908
Visible distal opacification, n (%) 143 (29.2) 1652 (46.7) < 0.001
Severe distal disease, n (%) 251 (53.0) 1360 (39.6) < 0.001
One or more previous attempts, n (%) 185 (37.4) 1167 (32.9) 0.049
Retrograde approach, n (%) 207 (41.9) 1010 (28.5) < 0.001
AE, n (%) 24 (4.9) 89 (2.5) 0.005
Occlusion duration, n (%): < 0.001
3–6 months     112 (22.7)       1303 (36.7)    
7–12 months     109 (22.1)        864 (24.3)    
Over 12 months     273 (55.3)       1383 (39.0)    
Parameter Non-AE
(n = 3931)
AE
(n = 113)
P-value
Age [years] 64.0 (57.0–72.0) 66.0 (59.0–73.0) 0.056
Gender (male), n (%) 3363 (85.6) 86 (76.1) 0.007
Procedure success –  
not successful (n = 494)
Procedure success – successful 
(n = 3550)
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Parameter P-value
BMI [kg/m2] 28.0 (25.5–31.1) 27.7 (24.8–31.1) 0.275
Hypertension, n (%) 3154 (80.2) 99 (87.6) 0.067
Hypercholesterolemia, n (%) 3119 (79.3) 97 (85.8) 0.117
Diabetes, n (%) 1220 (33.3) 33 (31.7) 0.825
Smoker, n (%) 834 (22.7) 19 (18.3) 0.339
PAD, n (%) 407 (10.4) 21 (18.6) 0.008
COPD, n (%) 186 (4.7) 10 (8.8) 0.074
Prior stroke, n (%) 103 (2.6) 7 (6.2) 0.033
Previous MI, n (%) 1709 (44.6) 60 (53.6) 0.073
Previous CABG, n (%) 674 (17.2) 24 (21.2) 0.314
Previous PCI, n (%) 2017 (51.3) 59 (52.2) 0.927
GFR [ml/min/1.73 m2] 89.0 (69.0–110.8) 81.2 (67.3–101.7) 0.013
Left ventricular EF < 35%, n (%) 235 (6.0) 12 (10.6) 0.07
Number of diseased vessels, n (%): 0.683
1-vessel disease 1192 (30.9) 30 (27.0)
2-vessel disease 1217 (31.6) 37 (33.3)
3-vessel disease 1448 (37.5) 44 (39.6)
CTO artery, n (%): 0.707
RCA 2254 (57.4) 62 (54.9)
LAD 956 (24.3) 29 (25.7)
Cx 670 (17.1) 21 (18.6)
LM 30 (0.8) 0 (0.0)
CTO in bypass 17 (0.4) 1 (0.9)
CTO in side branch 108 (2.8) 4 (3.5) 0.555
Ostial CTO, n (%) 494 (12.6) 16 (14.2) 0.728
In stent CTO, n (%) 391 (9.9) 7 (6.2) 0.246
Bifurcation, n (%) 1085 (27.6) 37 (32.7) 0.273
Vessel diameter [mm] 3.0 (2.5–3.0) 3.0 (2.5–3.0) 0.805
CTO length [mm] 25.0 (15.0–35.0) 30.0 (18.0–40.0) 0.136
Collateral circulation type 2, n (%) 1043 (27.9) 38 (33.9) 0.195
Proximal tortuosity, n (%) 750 (19.5) 15 (13.4) 0.138
In CTO bend, n (%) 1285 (32.9) 47 (41.6) 0.067
Moderate and severe calcification, n (%) 1658 (42.4) 49 (43.4) 0.908
Blunt stump, n (%) 1702 (43.5) 47 (41.6) 0.765
Side branch 3 mm proximal to CTO, n (%) 1041 (26.5) 35 (31.0) 0.338
Visible distal opacification, n (%) 1743 (44.6) 52 (46.0) 0.834
Severe distal disease, n (%) 1567 (41.3) 44 (38.9) 0.69
One or more previous attempts, n (%) 1315 (33.5) 37 (32.7) 0.955
Retrograde approach, n (%) 1165 (29.6) 52 (46.0) < 0.001
Procedural failure, n (%) 470 (12.0) 24 (21.2) 0.005
Occlusion duration, n (%): 0.024
3–6 months 1386 (35.3)    29 (25.7)     
7–12 months 949 (24.1)    24 (21.2)     
Over 12 months 1596 (40.6)    60 (53.1)     
Values are median (25th – 75th percentile) or n (%). AE – adverse events, BMI – body mass index, CABG – coronary artery bypass grafting, COPD – chronic obstructive 
pulmonary disease, CTO – chronic total occlusion, Cx – circumflex artery, EF – ejection fraction, GFR – glomerular filtration rate, LAD – left anterior descending artery, 
LM – left main artery, MI – myocardial infarction, PAD – peripheral artery disease, PCI – percutaneous coronary intervention, RCA – right coronary artery. For calcifi-
cation, lesion length and collateral circulation only clinical predictors were included in the analysis. For procedural success and AE clinical, lesion characteristics and 
retrograde approach were included in the analysis.
Non-AE
(n = 3931)
AE
(n = 113)
Table IV. Cont.
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Table V. Predictors for lesion characteristics and adverse events – multivariate analysis
Variable OR 95% CI
lower bound
95% CI  
upper bound
P-value
Calcification (moderate or severe):
Occlusion duration 7–12 months 1.14 0.95 1.38 0.165
Occlusion duration > 12 months 1.52 1.28 1.8 < 0.001
Collateral circulation type 2:
Occlusion duration 7–12 months 1.26 1.03 1.53 0.021
Occlusion duration > 12 months 1.2 1.01 1.43 0.041
Lesion length 20 mm:
Occlusion duration 7–12 months 1.43 1.19 1.72 < 0.001
Occlusion duration > 12 months 1.77 1.49 2.1 < 0.001
Procedural success:
Occlusion duration 7–12 months 0.78 0.57 1.06 0.116
Occlusion duration > 12 months 0.6 0.46 0.79 < 0.001
AE:
Occlusion duration 7–12 months 1.17 0.67 2.03 0.578
Occlusion duration > 12 months 1.56 0.98 2.47 0.06
Only results for occlusion duration (as compared to occlusion duration 3–6 months) are presented in the table. Full multivariate analysis is presented in Table VI. 
AE – adverse events, CI – confidence interval, CTO – chronic total occlusion, OR – odds ratio. Number of patients included in the analysis (n): calcification (moderate 
or severe), n = 3589; collateral circulation type 2, n = 3739; Lesion length 20 mm, n = 3815; AE, n = 4037.
during the hospitalization period. A recent study showed 
that complications during PCI of CTO were more frequent 
in females [28]. In concordance with that observation, fe-
male gender was one of two AE predictors in our study. 
Not surprisingly, the retrograde approach was the other 
predictor of AEs as this approach is considered as more 
complex when compared to the antegrade approach 
[6, 29]. However, it should be noted that the retrograde 
approach is often used in very advanced lesions where the 
antegrade approach is not feasible or ended with failure. 
Importantly, although patients with the longest CTO du-
ration had higher incidence of AEs as compared to the 
patients with the shortest CTO duration, the age of the 
CTO was not an independent predictor of AEs. Barlis 
et al. in their study compared AEs in patients with unde-
termined and known occlusion duration [30]. In long-term 
follow-up they found that undetermined occlusion dura-
tion was a predictor of AEs. In contrast to our study they 
did not find any differences in in-hospital outcomes be-
tween groups with known and unknown occlusion dura-
tion. However, their study was limited by the sample size. 
Limitations
First, our study is limited by its observational design. 
Second, angiography-dependent and clinical outcomes 
were not independently adjudicated. Third, data regard-
ing patients and lesion and procedural characteristics 
were missing in some cases. Moreover, only in half of 
the patients could CTO age be assessed. Out of 10 699 
patients, 4044 (37.8%) were included in the final anal-
ysis, which could have involved selection bias. Further, 
patients excluded from the study differed from those 
included in important lesion characteristics such as le-
sion location, number of previous attempts and severity 
of coronary artery disease. Lastly, the exact age of the 
CTO is often unclear. Hence, it is often very challenging 
to determine the exact age of the CTO.
Conclusions
Longer CTO duration is associated with greater prev-
alence of calcification, longer lesions, and better devel-
oped collateral circulation. Most importantly, in our study 
longer CTO duration was associated with lower revascu-
larization success by PCI. However, it did not affect the 
rate of in-hospital AEs. Our results should be taken into 
account when planning procedures of CTO older than 
12 months.
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Table VI. Full multivariate analysis
Parameter OR 95% CI lower bound 95% CI upper bound P-value
Calcification (moderate or severe):
Age 1.03 1.02 1.04 < 0.001
Gender (male) 1.31 1.06 1.61 0.011
BMI 1.02 1 1.03 0.038
Occlusion duration 7–12 months1 1.14 0.95 1.38 0.165
Occlusion duration over 12 months1 1.52 1.28 1.8 < 0.001
Hypertension 1.13 0.94 1.37 0.201
Hypercholesterolemia 1.21 1.01 1.45 0.038
Diabetes 1.21 1.03 1.41 0.017
Smoker 0.86 0.72 1.03 0.107
PAD 1.4 1.11 1.76 0.005
COPD 1.64 1.19 2.27 0.003
Previous CABG 1.58 1.28 1.96 < 0.001
Previous PCI 1.14 0.98 1.31 0.084
CKD class 4 2.45 1.4 4.31 0.002
2-vessel CAD disease 1.46 1.21 1.75 < 0.001
3- vessel CAD disease 1.82 1.51 2.2 < 0.001
CTO in bypass2 0.02 0 0.16 < 0.001
CTO in LAD2 0.85 0.72 1.01 0.068
CTO in Cx2 0.51 0.41 0.63 < 0.001
CTO in LM2 5.31 1.21 23.17 0.027
CTO in side branch 0.41 0.26 0.66 < 0.001
Ostial CTO 2.07 1.66 2.6 < 0.001
Collateral circulation 2:
Age 1 1 1.01 0.472
Gender (male) 1.47 1.18 1.83 0.001
BMI 0.99 0.98 1.01 0.394
Occlusion duration 7–12 months1 1.26 1.03 1.53 0.021
Occlusion duration over 12 months1 1.2 1.01 1.43 0.041
Previous CABG 1.46 1.17 1.82 0.001
Left ventricular EF < 35% 0.67 0.48 0.94 0.022
2-vessel CAD disease 0.79 0.66 0.94 0.01
3-vessel CAD disease 0.66 0.54 0.8 < 0.001
CTO in bypass2 0.14 0.02 1.08 0.059
CTO in LAD2 0.88 0.74 1.05 0.154
CTO in Cx2 0.57 0.46 0.72 < 0.001
CTO in LM2 1.45 0.65 3.23 0.362
CTO in side branch 0.31 0.16 0.6 0.001
Ostial CTO 1.49 1.2 1.85 < 0.001
Lesion length > 20 mm:
Age 0.99 0.98 1 0.019
Gender (male) 1.19 0.97 1.45 0.087
BMI 1.02 1 1.03 0.05
Occlusion duration 7–12 months1 1.43 1.19 1.72 < 0.001
Occlusion duration over 12 months1 1.77 1.49 2.1 < 0.001
PAD 1.27 0.99 1.64 0.059
Previous MI 1.12 0.96 1.3 0.146
Previous CABG 1.17 0.93 1.48 0.183
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Parameter OR 95% CI lower bound 95% CI upper bound P-value
Previous PCI 1.19 1.03 1.38 0.022
2-vessel CAD disease 1.03 0.86 1.23 0.749
3-vessel CAD disease 1.17 0.96 1.42 0.112
CTO in bypass2 1.71 0.38 7.79 0.488
CTO in LAD2 0.6 0.51 0.71 < 0.001
CTO in Cx2 0.52 0.43 0.64 < 0.001
CTO in LM2 0.27 0.12 0.61 0.002
CTO in side branch 0.32 0.21 0.48 < 0.001
Ostial CTO 1.85 1.44 2.37 < 0.001
Procedural success:
Age 0.99 0.97 1 0.015
Gender (male) 1 0.73 1.37 0.997
BMI 0.98 0.96 1.01 0.132
Occlusion duration 7–12 months1 0.78 0.57 1.06 0.116
Occlusion duration over 12 months1 0.6 0.46 0.79 < 0.001
Diabetes 0.89 0.71 1.12 0.314
PAD 0.7 0.51 0.95 0.024
COPD 0.61 0.4 0.93 0.022
Prior stroke 0.65 0.37 1.12 0.122
Previous CABG 1.01 0.76 1.34 0.956
Previous PCI 0.61 0.49 0.77 < 0.001
CTO in bypass2 2.99 0.37 24.24 0.305
CTO in LAD2 0.99 0.75 1.3 0.917
CTO in Cx2 1.27 0.92 1.76 0.148
CTO in LM2 6.48 0.83 50.51 0.075
Ostial CTO 0.58 0.43 0.78 < 0.001
In stent CTO 1.9 1.23 2.93 0.004
Lesion length > 20 mm 0.61 0.46 0.83 0.001
Proximal tortuosity 0.85 0.66 1.11 0.239
In CTO bend 0.57 0.46 0.71 < 0.001
Moderate/severe calcification 0.55 0.43 0.7 < 0.001
Blunt stump 0.79 0.63 0.98 0.034
Visible distal opacification 1.77 1.39 2.24 < 0.001
Severe distal disease 0.99 0.79 1.26 0.965
One or more previous attempts 0.87 0.69 1.09 0.231
AE:
Age 1.01 0.99 1.03 0.313
Gender (male) 0.52 0.33 0.81 0.004
BMI 0.98 0.94 1.03 0.44
Occlusion duration 7–12 months1 1.17 0.67 2.03 0.578
Occlusion duration over 12 months1 1.56 0.98 2.47 0.06
PAD 1.67 1.02 2.76 0.043
Prior stroke 2.09 0.93 4.73 0.075
Retrograde approach 1.93 1.31 2.83 0.001
AE – adverse events, BMI – body mass index, CABG – coronary artery bypass grafting, CAD – coronary artery disease, CI – confidence interval, CKD – chronic kidney 
disease, COPD – chronic obstructive pulmonary disease, CTO – chronic total occlusion, Cx – circumflex artery, EF – ejection fraction, LAD – left anterior descending 
artery, LM – left main artery, OR – odds ratio, PAD – peripheral artery disease, PCI – percutaneous coronary intervention. 1As compared to occlusion duration 3–6 
months; 2as compared to right coronary artery. For calcification, lesion length and collateral circulation only clinical predictors were included in the analysis. For 
procedural success and AE clinical, lesion characteristics and retrograde approach were included in the analysis. Number of patients included in the analysis (n): 
calcification (moderate or severe), n = 3589; collateral circulation type 2, n = 3739; lesion length 20 mm, n = 3815; procedural success, n = 3513; AE, n = 4037.
Table VI. Cont.
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Table VII. Comparison between patients with undetermined age of the occlusion and known occlusion duration
Parameter Undetermined age of the 
occlusion (n = 5033)
Known occlusion duration  
(n = 4044)
P-value
Age [years] 64.0 (57.0–72.0) 64.0 (57.0–72.0) 0.862
Gender (male), n (%) 4246 (84.4) 3449 (85.3) 0.239
BMI [kg/m2] 27.7 (25.1–30.7) 28.0 (25.4–31.1) < 0.001
Hypertension, n (%) 3824 (76.0) 3253 (80.4) < 0.001
Hypercholesterolemia, n (%) 3548 (70.5) 3216 (79.5) < 0.001
Diabetes, n (%) 1546 (32.9) 1253 (33.2) 0.78
Smoker, n (%) 1367 (29.1) 853 (22.6) < 0.001
PAD, n (%) 594 (11.8) 428 (10.6) 0.073
COPD, n (%) 262 (5.2) 196 (4.8) 0.466
Prior stroke, n (%) 147 (2.9) 110 (2.7) 0.611
Previous MI, n (%) 1807 (37.5) 1769 (44.8) < 0.001
Previous CABG, n (%) 406 (8.1) 698 (17.3) < 0.001
Previous PCI, n (%) 2492 (49.5) 2076 (51.3) 0.086
GFR [ml/min/1.73 m2] 86.9 (67.0–109.4) 88.6 (68.9–110.7) 0.006
Left ventricular EF < 35%, n (%) 412 (8.2) 247 (6.1) < 0.001
Number of diseased vessels, n (%): < 0.001
1-vessel disease 1677 (34.4) 1222 (30.8)
2-vessel disease 1654 (33.9) 1254 (31.6)
3-vessel disease 1549 (31.7) 1492 (37.6)
CTO artery, n (%): < 0.001
RCA 2746 (54.7) 2316 (57.3)
LAD 1338 (26.6) 985 (24.4)
Cx 914 (18.2) 691 (17.1)
LM 13 (0.3) 30 (0.7)
CTO in bypass 12 (0.2) 18 (0.4)
CTO in side branch 110 (2.2) 112 (2.8) 0.086
Ostial CTO 463 (9.2) 510 (12.6) < 0.001
In-stent CTO 369 (7.3) 398 (9.8) < 0.001
Bifurcation 1275 (25.3) 1122 (27.7) 0.01
Vessel diameter [mm] 3.0 (2.5–3.0) 3.0 (2.5–3.0) 0.136
CTO length [mm] 25.0 (15.0–35.0) 25.0 (15.0–35.0) 0.225
Collateral circulation type 2, n (%) 1443 (31.5) 1081 (28.1) 0.001
Proximal tortuosity, n (%) 941 (19.0) 765 (19.3) 0.714
In CTO bend, n (%) 1550 (31.0) 1332 (33.2) 0.034
Moderate and severe calcification, n (%) 2182 (43.5) 1707 (42.4) 0.294
Blunt stump, n (%) 2043 (40.7) 1749 (43.4) 0.01
Visible distal opacification, n (%) 2043 (41.0) 1795 (44.6) 0.001
Severe distal disease, n (%) 1721 (38.5) 1611 (41.2) 0.013
One or more previous attempts, n (%) 1115 (22.2) 1352 (33.4) < 0.001
Retrograde approach, n (%) 1411 (28.0) 1217 (30.1) 0.033
Procedural failure, n (%) 597 (11.9) 494 (12.2) 0.629
AE, n (%) 185 (3.7) 113 (2.8) 0.019
Radial access, n (%) 2324 (46.2) 1290 (31.9) < 0.001
Rotablation, n (%) 122 (12.4) 100 (2.5) 0.881
IVUS, n (%) 653 (13.0) 503 (12.4) 0.446
Procedure time 90.0 (60.0–129.0) 100.0 (63.0–144.0) < 0.001
Fluoroscopy time 33.0 (19.0–55.0) 37.0 (22.0–60.8) < 0.001
Dye used 236.0 (170.0–320.0) 250.0 (180.0–350.0) < 0.001
Values are median (25th–75th percentile) or n (%). AE – adverse events, BMI – body mass index, CABG – coronary artery bypass grafting, COPD – chronic obstructive 
pulmonary disease, CTO – chronic total occlusion, Cx – circumflex artery, EF – ejection fraction, GFR – glomerular filtration rate, LAD – left anterior descending artery, 
LM – left main artery, MI – myocardial infarction, PAD – peripheral artery disease, PCI – percutaneous coronary intervention, RCA – right coronary artery. Out of 
5933 patients with undetermined age of the occlusion, 900 were excluded due to insufficient data regarding the occlusion characteristics. In the end a total of 4044 
patients with known occlusion duration and 5033 patients with undetermined age of the occlusion were included in the data analysis.
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